

HEALTH SYSTEMS LAW AND POLICY CASES AND MATERIALS

VOLUME II

Colleen M. Flood

January-April 2004

Faculty of Law University of Toronto

These materials are not to be regarded as published. They have been reproduced for the exclusive use of students in the Faculty of Law, University of Toronto and for use as a classroom teaching tool.



HEALTH SYSTEMS LAW AND POLICY CASES AND MATERIALS


VOLUME II

Colleen M. Flood

January-April 2004

Faculty of Law University of Toronto

These materials are not to be regarded as published. They have been reproduced for the exclusive use of students in the Faculty of Law, University of Toronto and for use as a classroom teaching tool.



M	arch	9 th

Chapter Eight ACCESS TO AND THE PRICING OF PRESCRIPTION DRUGS

R. G. Elgie, "Regulating Prices of Patented Pharmaceuticals in Canada: The Patented Medicine Prices Review Board" (May 1996) 13: 2 Food, Drug, Cosmetic and Medical Device Law Digest 8083
M. Shuchman, "Drug firm threatens suit over M.D.'s product review," <i>Globe and Mail</i> , Wed., Nov. 17, 1999
S. Jacobzone, "Pharmaceutical Policies in OECD Countries: Reconciling Social and Industrial Goals (OECD Report: 2000)
Commission on the Future of Health Care in Canada, Building on Values: The Future of Health Care in Canada, Final Report, November 2002, Chapter 9 (pp189—201)
Daniel S. Greenberg, Medicare Reforms Receive Mixed Reaction, (2003) 362 The Lancet 1990
Drew D. Altman, The New Medicare Prescription-Drug Legilsation (2004) 350; 1 N Engl. J. Med. 9
M. M. Mellow, D. M. Studdert, and T. A. Brennan, "The Pharmaceutical Industry versus Medicaid – Limits on State Initiatives to Control Prescription-Drug CostsVIII, 61-67

